FibroBiologics, Inc. ( (FBLG) ) has issued an announcement.

Discover the latest on Akero Therapeutics, Inc., a biotech firm focusing on metabolic balance therapies, with a market cap of ...

Yorkville agreed to advance to FibroBiologics the first $15 million available under the SEPA in three equal tranches to be evidenced by convertible promissory notes. The first tranche in the amount of ...

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures ...

Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Esophageal Cancer.

Real Betis stadium A new potential anti-cancer target - RUNX2 Luye's new anti-tumor drug clinical trial accepted; China's first compound liposome dru ...

Cardiovascular disease continues to lead as the primary cause of death across the globe, taking millions of lives every year.

Cardiovascular disease continues to lead as the primary cause of death across the globe, taking millions of lives every year.

Clarity Pharmaceuticals Ltd. has expanded its pipeline with a new fibroblast activation protein (FAP)-targeted radiopharmaceutical for the diagnosis and treatment of cancer. Clarity’s targeted copper ...

Crohn's disease, a type of chronic inflammatory bowel disease (IBD), often causes scar-like tissue to build up in the ...

Genescience Pharmaceuticals Co. Ltd. has identified fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer, osteochondrodysplasia and ...